PET Imaging of PARP with with [18F]olaparib".
Poly (ADP‐ribose) polymerase (PARP) inhibitors are increasingly being studied as cancer drugs, as single agents or as a part of combination therapies. Imaging of PARP using a radiolabeled inhibitor has been proposed for patient selection, outcome prediction, and dose optimization of novel PARP‐targeting agents.
We have synthesised the fluorine-18 radiolabelled version of olaparib, an FDA-approved PARP inhibitor, and tested it in vitro and in vivo with promising results, and are now moving the first steps towards the clinical evaluation of this novel imaging agent.
Date:
20 November 2018, 13:30 (Tuesday, 7th week, Michaelmas 2018)
Venue:
Old Road Campus Research Building, Headington OX3 7DQ
Venue Details:
Room 71a, b & c
Speaker:
Anna Pacelli (University of Oxford)
Organising department:
Department of Oncology
Organiser:
Anne-Marie Honeyman-Tafa (University of Oxford)
Organiser contact email address:
anne-marie.honeyman-tafa@oncology.ox.ac.uk
Host:
Dr Bart Cornelissen (University of Oxford)
Part of:
CRUK & EPSRC Cancer Imaging Centre in Oxford
Booking required?:
Not required
Audience:
members of the CICO community and interested parties in the University or NHS
Editor:
Anne-Marie Honeyman-Tafa
